CASI Pharmaceuticals, Inc (DE)
CASIDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000895051
CASI Pharmaceuticals, Inc (DE) was delisted in 2023; its insiders filed their last Form 4 on Sep 9, 2022; 23 institutions reported holding it in 13F filings for Q4 2022, worth $3.31M in total; no superinvestor held it.
Q1 2023 vs. Q4 2022
How the institutions holding CASI Pharmaceuticals, Inc (DE) changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 23 | 0 | −23 |
| Shares | 1.87M | 0 | −1.87M (−100.0%) |
| Value | $3.31M | $0 | −$3.31M (−100.0%) |
New holders (0)
Institutions that held CASI Pharmaceuticals, Inc (DE) at the end of Q1 2023 but not at the end of Q4 2022.
None.
Sold out (23)
Institutions that held CASI Pharmaceuticals, Inc (DE) at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Federated Hermes, Inc. | 900,651 | $1.58M |
| Vanguard Group Inc | 257,618 | $461.1K |
| Wellington Shields Capital Management, LLC | 206,148 | $369.0K |
| Wellington Shields & Co., LLC | 145,315 | $260.1K |
| Geode Capital Management, LLC | 98,133 | $171.0K |
| BlackRock Inc. | 91,715 | $164.2K |
| Susquehanna International Group, LLP | 57,395 | $100.4K |
| State Street Corp | 35,555 | $62.2K |
| Northern Trust Corp | 25,593 | $45.8K |
| Franklin Resources Inc | 24,546 | $43.0K |
| Dimensional Fund Advisors LP | 11,508 | $21.0K |
| Renaissance Technologies LLC | 10,900 | $20.0K |
| Tower Research Capital LLC (TRC) | 3,494 | $7.00K |
| Morgan Stanley | 1,946 | $3.48K |
| UBS Group AG | 1,423 | $2.55K |
| Wells Fargo & Company | 62 | $111 |
| Northwestern Mutual Wealth Management Co | 13 | $23 |
| Bank of America Corp | 12 | $21 |
| Colonial Trust Co | 11 | $20 |
| JPMorgan Chase & Co | 25 | $0 |
| Royal Bank of Canada | 58 | $0 |
| Advisor Group Holdings, Inc. | 200 | $0 |
| IFP Advisors, Inc | 9 | – |